Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I MAD Study of Ruzinurad in Males with High Serum Uric Acid
NCT03211403Phase 1Completed
- Sponsor
- Atridia Pty Ltd
- Start
- Jul 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ruzinurad in hyperuricemia (3 arms), sponsored by Atridia Pty Ltd. Primary endpoints: Incidence of Adverse events in terms of changes in Hematology, Incidence of Adverse events in terms of changes in Urinalysis and 4 more. Started Jul 2017; status: completed.
02
Drugs
ruzinurad
03
Conditions
hyperuricemia
Beyond the preview
Go deeper on NCT03211403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03211403.